Know Cancer

forgot password

SS-GCC1- Screening Study of Genetic Changes in Colorectal Cancer

18 Years
Open (Enrolling)
Colorectal Cancer

Thank you

Trial Information

SS-GCC1- Screening Study of Genetic Changes in Colorectal Cancer

All patients at the Royal Marsden with a diagnosis of colorectal cancer will be eligible to
enter this study. This will include patients both with early and advanced disease, provided
they give informed consent. They will give written consent to participate, to include
consent for analysis of existing tumour tissue and consent for collection of demographic and
clinicopathological data relating to their case and its future outcome, and consent for a
blood sample to be taken for research purposes. Additionally, old samples of material
surplus to clinical requirements may be collected without specific consent if there is no
possibility that it would affect the patient's interest (eg the patient has died).

Inclusion Criteria:

- adults who have a terminal illness

- 18 and over

- confirmed diagnosis of colorectal carcinoma

- ability to give informed consent

- paraffin embedded histological material available for analysis

Exclusion Criteria:

- medical or psychiatric conditions

- impairing ability to give informed consent

Type of Study:


Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

the primary endpoint is the identification of cases with evidence of loss of the product of one of the four main MMR genes on tumour histology.

Principal Investigator

Prof Cunningham, David

Investigator Role:

Principal Investigator

Investigator Affiliation:

Royal Marsden NHS Foundation Trust


United Kingdom: Research Ethics Committee

Study ID:




Start Date:

November 2008

Completion Date:

June 2016

Related Keywords:

  • Colorectal Cancer
  • colorectal
  • cancer
  • gene expression
  • biomarker
  • genomic mismatch repair
  • Colorectal Neoplasms